Travere Therapeutics Stock Price History
TVTX Stock | USD 18.70 0.36 1.89% |
Below is the normalized historical share price chart for Travere Therapeutics extending back to August 13, 2003. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Travere Therapeutics stands at 18.70, as last reported on the 28th of November, with the highest price reaching 18.70 and the lowest price hitting 18.70 during the day.
If you're considering investing in Travere Stock, it is important to understand the factors that can impact its price. Travere Therapeutics is not too volatile given 3 months investment horizon. Travere Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.26, which indicates the firm had a 0.26% return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.18% are justified by taking the suggested risk. Use Travere Therapeutics Risk Adjusted Performance of 0.2173, semi deviation of 1.92, and Coefficient Of Variation of 365.74 to evaluate company specific risk that cannot be diversified away.
At this time, Travere Therapeutics' Other Stockholder Equity is fairly stable compared to the past year. Sale Purchase Of Stock is likely to rise to about 32.7 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 168 M in 2024. . At this time, Travere Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. Price Earnings To Growth Ratio is likely to rise to 0.1 in 2024, whereas Price Earnings Ratio is likely to drop (6.29) in 2024. Travere Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 8th of November 2012 | 200 Day MA 10.2583 | 50 Day MA 16.8507 | Beta 0.7 |
Travere |
Sharpe Ratio = 0.2573
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | TVTX | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
4.6 actual daily | 40 60% of assets are more volatile |
Expected Return
1.18 actual daily | 23 77% of assets have higher returns |
Risk-Adjusted Return
0.26 actual daily | 20 80% of assets perform better |
Based on monthly moving average Travere Therapeutics is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Travere Therapeutics by adding it to a well-diversified portfolio.
Price Book 76.1026 | Enterprise Value Ebitda (5.67) | Price Sales 8.1538 | Shares Float 57.9 M | Wall Street Target Price 26.9375 |
Travere Therapeutics Stock Price History Chart
There are several ways to analyze Travere Stock price data. The simplest method is using a basic Travere candlestick price chart, which shows Travere Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | November 8, 2024 | 19.85 |
Lowest Price | September 5, 2024 | 9.93 |
Travere Therapeutics November 28, 2024 Stock Price Synopsis
Various analyses of Travere Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Travere Stock. It can be used to describe the percentage change in the price of Travere Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Travere Stock.Travere Therapeutics Price Rate Of Daily Change | 0.98 | |
Travere Therapeutics Price Action Indicator | (0.18) |
Travere Therapeutics November 28, 2024 Stock Price Analysis
Travere Stock Price History Data
The price series of Travere Therapeutics for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 has a statistical range of 10.82 with a coefficient of variation of 19.5. The price distribution for the period has arithmetic mean of 15.55. The median price for the last 90 days is 17.3. The company completed stock split (1:9) on 8th of November 2011.Open | High | Low | Close | Volume | ||
11/28/2024 | 19.06 | 18.70 | 18.70 | 18.70 | ||
11/27/2024 | 19.10 | 19.23 | 18.69 | 18.70 | 917,901 | |
11/26/2024 | 18.33 | 19.12 | 18.19 | 19.06 | 1,767,140 | |
11/25/2024 | 18.72 | 18.73 | 18.14 | 18.18 | 983,509 | |
11/22/2024 | 18.40 | 18.93 | 18.03 | 18.25 | 1,102,917 | |
11/21/2024 | 17.96 | 18.64 | 17.89 | 18.26 | 905,919 | |
11/20/2024 | 17.36 | 17.87 | 17.05 | 17.86 | 947,239 | |
11/19/2024 | 17.39 | 17.44 | 16.98 | 17.39 | 975,258 | |
11/18/2024 | 17.69 | 17.86 | 16.86 | 17.39 | 1,644,855 | |
11/15/2024 | 18.52 | 18.56 | 17.32 | 17.72 | 1,473,287 | |
11/14/2024 | 18.65 | 18.99 | 18.21 | 18.47 | 1,266,357 | |
11/13/2024 | 19.00 | 19.51 | 18.50 | 18.56 | 1,255,789 | |
11/12/2024 | 18.76 | 19.22 | 18.55 | 18.75 | 1,307,644 | |
11/11/2024 | 19.79 | 20.33 | 19.00 | 19.03 | 1,271,507 | |
11/08/2024 | 17.66 | 19.93 | 17.17 | 19.85 | 3,981,870 | |
11/07/2024 | 17.26 | 17.92 | 17.17 | 17.66 | 951,183 | |
11/06/2024 | 18.48 | 18.69 | 17.24 | 17.30 | 1,531,412 | |
11/05/2024 | 18.05 | 18.10 | 17.32 | 17.75 | 868,748 | |
11/04/2024 | 17.35 | 18.50 | 16.89 | 18.10 | 1,334,043 | |
11/01/2024 | 17.95 | 18.56 | 17.40 | 17.57 | 1,941,314 | |
10/31/2024 | 16.80 | 18.28 | 16.77 | 17.50 | 1,641,798 | |
10/30/2024 | 18.46 | 18.90 | 17.68 | 17.76 | 2,672,274 | |
10/29/2024 | 17.77 | 18.39 | 17.48 | 18.37 | 838,520 | |
10/28/2024 | 17.85 | 18.29 | 17.65 | 17.88 | 865,323 | |
10/25/2024 | 18.19 | 18.32 | 17.41 | 17.53 | 929,998 | |
10/24/2024 | 17.88 | 18.20 | 17.55 | 18.09 | 1,273,668 | |
10/23/2024 | 17.83 | 18.43 | 17.57 | 17.96 | 975,017 | |
10/22/2024 | 17.84 | 18.25 | 17.64 | 17.97 | 771,388 | |
10/21/2024 | 19.12 | 19.25 | 17.55 | 18.10 | 982,858 | |
10/18/2024 | 18.19 | 18.34 | 17.55 | 17.87 | 858,254 | |
10/17/2024 | 18.05 | 18.82 | 17.76 | 18.25 | 1,019,584 | |
10/16/2024 | 18.20 | 18.34 | 17.69 | 18.05 | 1,114,898 | |
10/15/2024 | 17.50 | 17.77 | 17.00 | 17.69 | 1,662,402 | |
10/14/2024 | 16.46 | 17.49 | 16.17 | 17.44 | 1,668,794 | |
10/11/2024 | 17.05 | 18.00 | 16.35 | 16.41 | 4,328,178 | |
10/10/2024 | 17.59 | 18.60 | 16.74 | 17.11 | 3,484,911 | |
10/09/2024 | 15.65 | 17.77 | 15.50 | 17.59 | 5,699,170 | |
10/08/2024 | 15.31 | 15.61 | 13.90 | 15.21 | 3,593,994 | |
10/07/2024 | 15.24 | 15.58 | 14.02 | 15.26 | 2,668,447 | |
10/04/2024 | 13.87 | 15.46 | 13.82 | 15.23 | 3,178,806 | |
10/03/2024 | 13.86 | 14.03 | 13.24 | 13.65 | 1,243,004 | |
10/02/2024 | 14.01 | 14.25 | 13.71 | 13.87 | 3,650,203 | |
10/01/2024 | 13.74 | 14.21 | 13.40 | 13.99 | 1,786,285 | |
09/30/2024 | 14.30 | 14.41 | 13.70 | 13.99 | 1,977,219 | |
09/27/2024 | 14.18 | 14.90 | 13.97 | 14.01 | 2,934,692 | |
09/26/2024 | 14.71 | 15.33 | 14.48 | 15.04 | 1,937,913 | |
09/25/2024 | 14.61 | 15.19 | 14.37 | 14.54 | 1,662,479 | |
09/24/2024 | 14.55 | 14.86 | 14.17 | 14.56 | 1,448,523 | |
09/23/2024 | 15.36 | 15.36 | 14.39 | 14.51 | 1,774,961 | |
09/20/2024 | 14.98 | 15.26 | 14.67 | 15.21 | 4,002,523 | |
09/19/2024 | 14.69 | 15.23 | 14.41 | 15.06 | 1,784,990 | |
09/18/2024 | 14.37 | 14.75 | 14.05 | 14.35 | 1,982,772 | |
09/17/2024 | 14.32 | 14.79 | 14.01 | 14.40 | 2,750,045 | |
09/16/2024 | 13.41 | 14.72 | 13.22 | 14.27 | 3,738,986 | |
09/13/2024 | 12.89 | 13.57 | 12.57 | 13.48 | 2,318,126 | |
09/12/2024 | 12.12 | 12.74 | 11.89 | 12.60 | 1,331,086 | |
09/11/2024 | 12.68 | 12.72 | 12.13 | 12.24 | 1,315,502 | |
09/10/2024 | 12.90 | 13.18 | 12.40 | 12.84 | 1,972,245 | |
09/09/2024 | 11.52 | 13.16 | 11.50 | 12.86 | 4,210,428 | |
09/06/2024 | 10.80 | 11.91 | 10.64 | 10.98 | 7,892,687 | |
09/05/2024 | 10.15 | 10.36 | 9.44 | 9.93 | 1,121,795 |
About Travere Therapeutics Stock history
Travere Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Travere is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Travere Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Travere Therapeutics stock prices may prove useful in developing a viable investing in Travere Therapeutics
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 74.3 M | 45.7 M | |
Net Loss | -250.6 M | -238.1 M |
Travere Therapeutics Quarterly Net Working Capital |
|
Travere Therapeutics Stock Technical Analysis
Travere Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
All Next | Launch Module |
Travere Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Travere Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Travere Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Travere to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.2173 | |||
Jensen Alpha | 1.08 | |||
Total Risk Alpha | 0.5111 | |||
Sortino Ratio | 0.421 | |||
Treynor Ratio | 1.03 |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.